Scarica l'app Stockscreener
2.60
0.39%
0.01
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IBRX Giù?
Forum
Previsione
Precedente Chiudi:
$2.59
Aprire:
$2.58
Volume 24 ore:
7.70M
Relative Volume:
0.92
Capitalizzazione di mercato:
$2.46B
Reddito:
$1.31M
Utile/perdita netta:
$-597.65M
Rapporto P/E:
-2.6804
EPS:
-0.97
Flusso di cassa netto:
$-425.62M
1 W Prestazione:
+8.33%
1M Prestazione:
+5.26%
6M Prestazione:
-9.41%
1 anno Prestazione:
-25.50%
Intervallo 1D:
$2.54
$2.62
Intervallo di 1 settimana:
$2.32
$2.67
Portata 52W:
$1.83
$7.48
Immunitybio Inc Stock (IBRX) Company Profile
Nome
Immunitybio Inc
Settore
Industria
Telefono
(844) 696-5235
Indirizzo
3530 JOHN HOPKINS COURT, SAN DIEGO
Confronta IBRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
2.60 | 2.43B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-20 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-10 | Iniziato | BTIG Research | Buy |
| 2023-05-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | Iniziato | Jefferies | Buy |
Immunitybio Inc Borsa (IBRX) Ultime notizie
Why ImmunityBio Inc. stock remains a top recommendationJuly 2025 Gainers & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
HC Wainwright Reaffirms "Buy" Rating for ImmunityBio (NASDAQ:IBRX) - MarketBeat
ImmunityBio (NASDAQ:IBRX) Stock Price Up 7.3%Should You Buy? - MarketBeat
ImmunityBio: Still Too Early To Judge Anktiva, Although Clock Is Ticking (NASDAQ:IBRX) - Seeking Alpha
Breakthrough Findings from Phase 2 QUILT-3.055 Study in NSCLCImmunityBio, Inc. - Oncodaily
H.C. Wainwright reiterates Buy rating on ImmunityBio stock, citing promising lung cancer data - Investing.com India
ImmunityBio (NASDAQ:IBRX) Given Buy Rating at D. Boral Capital - MarketBeat
Why ImmunityBio, Inc. (IBRX) Surged On Thursday - MSN
ImmunityBio’s Innovative Phase 2 Lymphoma Study: A Potential Game-Changer? - MSN
Sentiment Review: Is ImmunityBio Inc. a cyclical or defensive stock2025 Momentum Check & AI Forecasted Entry/Exit Points - Lancaster City Council
ImmunityBio Stock Rebounds: Bright Outlook Ahead? - StocksToTrade
ImmunityBio’s Stock Surge: Health Revolution or Hype? - timothysykes.com
ImmunityBio’s Surprising Performance: What Lies Ahead? - StocksToTrade
Decliners Report: Is ImmunityBio Inc. gaining market shareMarket Sentiment Summary & Fast Moving Trade Plans - Lancaster City Council
Risk Hedge: Does ImmunityBio Inc. have a sustainable dividendJuly 2025 Volume & Long Hold Capital Preservation Tips - Lancaster City Council
ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy - BioSpace
ImmunityBio Inc. Shows Early Signs of Technical StrengthQuarterly Performance Summary & Technical Pattern Alert System - beatles.ru
Investors Can Still File Late Claims in ImmunityBio Settlement — Here’s How to Get Your Share - TradingView
Is ImmunityBio Inc. stock technically oversoldM&A Rumor & Weekly Top Performers Watchlists - beatles.ru
ImmunityBio’s Anktiva: A Promising Treatment for Long COVID? - TipRanks
Real time scanner hits for ImmunityBio Inc. explainedWeekly Market Outlook & AI Powered Trade Plan Recommendations - Newser
What momentum shifts mean for ImmunityBio Inc.Analyst Downgrade & Consistent Profit Trade Alerts - Newser
A Closer Look at ImmunityBio (IBRX) Valuation Following Promising Early Results in Glioblastoma Study - Yahoo Finance
Rafferty Asset Management LLC Lowers Stock Holdings in ImmunityBio, Inc. $IBRX - MarketBeat
Is ImmunityBio Inc. gaining market shareMarket Trend Report & Weekly Chart Analysis and Guides - خودرو بانک
Is ImmunityBio Inc. a speculative investment2025 Key Highlights & Free Fast Gain Swing Trade Alerts - 강소기업뉴스
Is ImmunityBio Inc. reversing from oversold territoryJuly 2025 Reactions & Technical Entry and Exit Alerts - Newser
ImmunityBio Inc. stock volume spike explainedJuly 2025 Action & Momentum Based Trading Ideas - Newser
How to build a custom watchlist for ImmunityBio Inc.Gap Down & Weekly High Return Forecasts - Newser
What’s next for ImmunityBio Inc. stock price2025 Biggest Moves & Daily Stock Trend Watchlist - Newser
Advanced analytics toolkit walkthrough for ImmunityBio Inc.Weekly Investment Recap & Weekly Breakout Stock Alerts - Newser
Applying chart zones and confluence areas to ImmunityBio Inc.Quarterly Portfolio Report & Expert Curated Trade Setups - Newser
ImmunityBio (IBRX) Reports 60% Revenue Growth as ANKTIVA Adoption Accelerates - MSN
ImmunityBio Inc. stock prediction for this week2025 Top Gainers & Technical Confirmation Trade Alerts - Newser
Using R and stats models for ImmunityBio Inc. forecasting2025 Price Action Summary & Low Risk Entry Point Tips - Newser
Will ImmunityBio Inc. bounce back from current supportJuly 2025 Patterns & Reliable Volume Spike Alerts - Newser
NK Cell Therapy Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies - The Globe and Mail
Osteoarthritis Pipeline Analysis, 2025 by DelveInsight | ImmunityBio, Five Prime Therapeutics, Innate Pharma, Nektar Therapeutics, Cantargia, CureTech, Dynavax, Cellid Company, Kiadis Pharma, Multimmu - Barchart.com
What Went Wrong With ImmunityBio’s Executives Claims — and How Investors Could Still Win - TradingView
Detecting price anomalies in ImmunityBio Inc. with AIJuly 2025 Trade Ideas & AI Enhanced Execution Alerts - Newser
Is ImmunityBio Inc. stock entering bullish territory2025 Trading Volume Trends & Comprehensive Market Scan Insights - Newser
Measuring ImmunityBio Inc.’s beta against major indicesMarket Rally & Long-Term Growth Stock Strategies - Newser
Aug Sentiment: Can ImmunityBio Inc. stock double in the next yearWeekly Risk Summary & Advanced Technical Signal Analysis - خودرو بانک
Custom strategy builders for tracking ImmunityBio Inc.Bull Run & Technical Confirmation Trade Alerts - Newser
Should I hold or sell ImmunityBio Inc. nowJuly 2025 Action & High Accuracy Buy Signal Tips - خودرو بانک
Is ImmunityBio Inc. stock a smart retirement pickJuly 2025 Volume & Momentum Based Trading Ideas - khodrobank.com
What are the analyst revisions for DRUGIs ImmunityBio Inc. stock a good investment in YEARTrade Exit Summary & Real-Time Volume Analysis - خودرو بانک
Should value investors consider ImmunityBio Inc.July 2025 Sector Moves & Precise Trade Entry Recommendations - خودرو بانک
Can ImmunityBio Inc. stock double in the next year2025 Market Overview & AI Driven Price Predictions - خودرو بانک
Immunitybio Inc Azioni (IBRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.93%
0.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):